Thursday, July 29

Moderna

ensayos, gripe, gripe estacional, Moderna, Noticias, Salud, vacuna

Moderna begins trials of a flu vaccine | Digital Trends Spanish

Moderna has announced that its quadrivalent seasonal flu mRNA candidate vaccine has begun clinical trials. The pharmaceutical company reported that it administered its vaccine to the first group of volunteers in a clinical trial, marking the next stage of the company's work in these types of technologies after the success of its ani-COVID-19 vaccine. The efficacy of mRNA vaccines against coronavirus represented an important support for this type of drug. Now, drug companies plan to use this technology to fight other types of infectious diseases, including the flu. Moderna hopes that mRNA-based flu vaccines will be more effective than traditional ones. Being faster to manufacture, production would not have to start that far in advance and could theoretically be better suited to the typ...
coronavirus, Covid 19, Derrick Rossi, Laboratorio Wuhan, Moderna, Noticias, Salud

Moderna founder: COVID-19 escaped from Wuhan | Digital Trends Spanish

The theory that the COVID-19 escaped from the Wuhan laboratory continues to gain more strength, and this Tuesday, June 29, the founder of Moderna, who already has one of the approved vaccines against the virus, referred to this thesis and declared that he was sure that everything came out of that mysterious place. The Canadian biologist and Princess of Asturias Award for Technical and Scientific Research, Derrick Rossi, He referred to this in an interview with the newspaper El Comercio. “We have no proof in any way, but this virus is so different from bats that it seems unlikely to me that it was a natural leap. It is a fact that a laboratory in Wuhan worked with him and I am convinced that he came out of there, that he escaped them. I don't think it was deliberate, they were just stu...
AstraZeneca, booster shot, coronavirus, COVID-19 vaccine, Johnson & Johnson, Moderna, Pfizer, Science

Early findings indicate that mixing and matching coronavirus vaccines might improve your protection

The evidence in favor of a mix-and-match approach to coronavirus shots is growing.Early data from a UK study, though not yet been peer reviewed, indicates that mixing the Pfizer and AstraZeneca vaccines yields a greater immune response than two doses of AstraZeneca's shot. The researchers measured antibody levels among 830 volunteers who received either two doses of the same vaccine or a combination of Pfizer and AstraZeneca, four weeks apart.Volunteers who got AstraZeneca's shot followed by Pfizer's showed nearly the same antibody levels — and an even higher number of T-cells — as those who'd received two doses of Pfizer. By contrast, volunteers who got Pfizer's shot first and AstraZeneca's second had slightly lower antibody...
BioNTech, coronavirus, Delta, Health, Healthcare, Johnson & Johnson, Moderna, mRNA, Pfizer, Science, Vaccine, variant

Some experts who had Johnson & Johnson’s single-dose vaccine are now getting extra shots of Pfizer or Moderna to try to protect against the Delta variant

Some experts who got Johnson & Johnson's one-dose vaccine are topping it up with a dose of Pfizer or Moderna. They did it for extra protection against the fast-spreading Delta coronavirus variant, they said. The FDA and CDC don't recommend getting an extra shot, after a J&J vaccine or otherwise. LoadingSomething is loading. ...
coronavirus, COVID-19 vaccine, Moderna, National Institutes of Health, Public Health, Science, Vaccine trials

A man who boosted his Pfizer COVID-19 vaccine with a shot from Moderna said his side effects were a’little more severe’ the third time round

Scientists in the US are starting a booster shot trial, giving fully vaccinated people another jab. Participants are given a booster shot of the Moderna vaccine — whether they previously got 2 shots of an mRNA vaccine (from Pfizer or Moderna) or 1 adenovirus (J&J) shot. One participant told Insider his booster dose of Moderna gave him similar side effects to his second Pfizer shot, but the third was "a little bit more severe." See more stories on Insider's business page. Virus expert Joseph Hyser has been fully vaccinated since the end of January, and he's not really worried that his COVID-19 protection from the Pfizer vaccine has...
AstraZeneca, BioNTech, coronavirus, Covid 19, Cuánto costará la vacuna, Moderna, Noticias, Pfizer, precio, Salud, vacuna

How much will vaccines for coronavirus cost? | Digital Trends Spanish

The US modern laboratory, which is in stage three of developing the coronavirus vaccine, revealed the price of the doses. The biotechnology company, which received funds from the Operation Warp Speed ​​program (which in Spanish means “Maximum Speed ​​Operation”) from the United States federal government, commented that it has US $ 400 million in customer deposits for a possible supply of its vaccine mRNA-1273. According to what it has estimated and announced, Moderna will market its doses at a price of $ 40 dollars, while the wholesale price would reach between $ 32 dollars to $ 37 dollars. Getty Images / Digital Trends Graphics In any case, Moderna's CEO, Stéphane Bancel, promised during a conference call with analysts that their vaccine would be affordable. “We are wo...
coronavirus, COVID19, Moderna, Noticias, Salud

COVID-19: China Linked to Attack on US Pharmaceutical | Digital Trends Spanish

The Moderna company was reportedly attacked by hackers who aimed to steal data from this biotechnology laboratory, one of which is leading the development of a coronavirus vaccine. This was stated by a United States security official quoted by Reuters, who claimed - on condition of anonymity - that the hackers had had the support of the Chinese government. The official did not provide further details, according to the British agency. Moderna is a United States-based company that is spearheading one of the most advanced projects to find a coronavirus pandemic vaccine. Their work runs parallel to that of the Chinese laboratories Sinovac and Sinopharm, in addition to the joint initiative between the University of Oxford and the pharmaceutical company AstraZeneca. According...
coronavirus, COVID19, Moderna, Noticias, pruebas de covid-19, Salud, vacuna

COVID-19: Primate Tests Support Moderna Vaccine | Digital Trends Spanish

The US biotechnology company Moderna Inc. said its candidate vaccine against COVID-19 showed a "robust immune response" and protection against SARS-CoV-2 infection in non-human primates. The results of the preclinical study, published in the journal The New England Journal of Medicine, showed that a two-dose vaccination program of the drug mRNA-1273, without registering the phenomenon called vaccine-associated increase in respiratory disease (VAERD). In the study, immunogenicity and protective efficacy were evaluated after a two-dose vaccination program of 10 or 100 micrograms of mRNA-1273. Four weeks after the second vaccination, the animals were subjected to high doses of SARS-CoV-2 intranasally and intratracheally. After two vaccines, the immune response observed in ...